Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2024

Earnings Per Share [Abstract]

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share

The Net loss per share - attributable to PAVmed Inc. - basic and diluted and Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
	2024			2023			2024			2023
Numerator
Net loss - before noncontrolling interest	$	(14,914	)	$	(17,892	)	$	(33,426	)	$	(40,106	)
Net loss attributable to noncontrolling interest		4,087			3,355			7,387			7,638
Net loss - as reported, attributable to PAVmed Inc.	$	(10,827	)	$	(14,537	)	$	(26,039	)	$	(32,468	)
Series B Convertible Preferred Stock dividends – earned	$	(81	)	$	(75	)	$	(161	)	$	(149	)
Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests	$	—		$	—		$	(7,496	)	$	—
Net loss attributable to PAVmed Inc. common stockholders	$	(10,908	)	$	(14,612	)	$	(33,696	)	$	(32,617	)
Denominator
Weighted average common shares outstanding, basic and diluted		9,152,819			6,956,655			8,923,862			6,716,169
Net loss per share (1)
Basic and diluted
Net loss attributable to PAVmed Inc. common stockholders	$	(1.19	)	$	(2.10	)	$	(3.78	)	$	(4.86	)

(1) - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share

	June 30,
	2024		2023
Stock options and restricted stock awards		1,691,512		1,263,715
Series Z Warrants		795,830		795,830
Series B Convertible Preferred Stock		90,532		83,634
Total		2,577,874		2,143,179